Removing the immune response from muscular dystrophy research

Molecular Therapy

Volumn 21, Issue 10, 2013, Pages 1821-1822

  Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROPHIN; PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; GENETIC MANIPULATION; HUMAN; IMMUNE RESPONSE; MISSENSE MUTATION; NONHUMAN; NOTE; PROTEIN EXPRESSION; STEM CELL GENE THERAPY; STEM CELL TRANSPLANTATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; DNA-BINDING PROTEINS; DYSTROPHIN; HUMANS; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MALE; MICE, INBRED MDX; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL;

EID: 84885002209     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.209     Document Type: Note

References (15)

1. Vallese, D, Negroni, E, Duguez, S, Ferry, A, Trollet, C, Aamiri, A et al. (2013). The Rag2-Il2rb-Dmd- mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies. Mol Ther 21: 1950-1957.
2. Emery, AE and Muntoni, F (2003). Duchenne Muscular Dystrophy. Oxford University Press: Oxford, UK.
3. Goyenvalle, A, Seto, JT, Davies, KE and Chamberlain, J (2011). Therapeutic approaches to muscular dystrophy. Hum Molec Genet 20: R69-R78.
4. Konieczny, P, Swiderski, K and Chamberlain, JS (2013). Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 47: 649-663.
5. Peault, B, Rudnicki, M, Torrente, Y, Cossu, G, Tremblay, JP, Partridge T et al. (2007). Stem and progenitor cells in skeletal muscle development, maintenance, and therapy. Mol Ther 15: 867-877.
6. Boldrin, L, Muntoni, F and Morgan, JE (2010). Are human and mouse satellite cells really the same? J Histochem Cytochem 58: 941-955.
7. Gussoni, E, Blau, HM and Kunkel, LM (1997). The fate of individual myoblasts after transplantation into muscles of DMD patients. Nat Med 3: 970-977.
8. Wertz, K and Fuchtbauer, EM (1998). Dmd(mdx-beta geo): a new allele for the mouse dystrophin gene. Dev Dyn 212: 229-241.
9. Ng, R, Banks, GB, Hall, JK, Muir, LA, Ramos, JN, Wicki, J et al. (2012). Animal models of muscular dystrophy. Prog Mol Biol Transl Sci 105: 83-111.
10. Danko, I, Chapman, V and Wolff, JA (1992). The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. Pediatr Res 32: 128-131.
11. Yokota, T, Lu, QL, Morgan, JE, Davies, KE, Fisher, R, Takeda, S et al. (2006). Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration. J Cell Sci 119: 2679-2687.
12. Spencer, MJ, Montecino-Rodriguez, E, Dorshkind, K and Tidball, JG (2001). Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophindeficient muscle. Clin Immunol 98: 235-243.
13. Arpke, RW, Darabi, R, Mader, TL, Zhang, Y, Toyama, A, Lonetree, CL et al. (2013). A new immuno- dystrophindeficient model, the NSG-mdx4Cv mouse, provides evidence for functional improvement following allogeneic satellite cell transplantation. Stem Cells; e-pub ahead of print 19 April 2013.
14. Chamberlain, JS (1997). Dystrophin levels required for correction of Duchenne muscular dystrophy. Basic Appl Myol 7: 251-255.
15. Mendell, JR, Campbell, K, Rodino-Klapac, L, Sahenk, Z, Shilling, C, Lewis, S et al. (2010). Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med 363: 1429-1437.